Evaluation on Thrombotic Events Frequency in JAK2 V617F Positive Patients

Abstract

The Polycythemia Vera is a myeloproliferative neoplasia whose overall incidence is 0.7-2.6 cases per 100.000 inhabitants/year; 92.3% of the patients were positive to the JAK2 V617F mutation (exon 14) and 7.7% were negative also to the mutations on the exon 12. Around 29.16% of the JAK2 V617F positive patients had arterial or venous thrombosis. The percentage of patients with the JAK2 V617F mutation and the frequency of thrombosis in PV JAK2 positive patients demonstrated in our study are according to the data presented in the literature.